Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 4.5% – Time to Buy?

Posted by Caroline Horne on Feb 19th, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) traded up 4.5% during trading on Monday . The company traded as high as $12.01 and last traded at $11.95. 371,678 shares traded hands during trading, a decline of 72% from the average session volume of 1,304,689 shares. The stock had previously closed at $11.43.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating on the stock.

View Our Latest Stock Analysis on TNXP

Tonix Pharmaceuticals Price Performance

The company’s 50-day moving average is $28.69 and its 200-day moving average is $23.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a market capitalization of $18.70 million, a price-to-earnings ratio of 0.00 and a beta of 2.07.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Commonwealth Equity Services LLC purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $40,000. Two Sigma Investments LP purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $66,000. PFG Investments LLC purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $72,000. Northern Trust Corp purchased a new position in Tonix Pharmaceuticals in the fourth quarter valued at approximately $162,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $526,000. Hedge funds and other institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.